Skip to main content

Table 2 Adverse events that occurred in at least 10% of patients

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

AE, n (%) All grade Grades 1–2 Grade ≥ 3
Pyrexia 52 (91) 41 (72) 11 (19)
Cytokine release syndromea 51 (90) 47 (83) 4 (7)
Thrombocytopenia 28 (49) 15 (26) 13 (23)
Leukopenia 27 (47) 10 (18) 17 (30)
AST increased 22 (39) 10 (18) 12 (21)
Anemia 17 (30) 7 (12) 10 (18)
Hypotension 12 (21) 9 (16) 3 (5)
ALT increased 10 (18) 10 (18) 0
Cough 10 (18) 10 (18) 0
Disseminated intravascular coagulation 10 (18) 9 (16) 1 (2)
Hypocalcemia 9 (16) 7 (12) 2 (4)
Hyponatremia 8 (14) 5 (9) 3 (5)
Dyspnea 6 (11) 6 (11) 0
Nausea 6 (11) 6 (11) 0
  1. ALT alanine aminotransferase, AST aspartate aminotransferase
  2. aCytokine release syndrome assessed using modified criteria by Lee et al. [25]